Key Metrics
CiteScore 

18.8
Eigenfactor 

0.01 - 0.05
H-Index 

150
Impact Factor 

15 - 20
Scite Index 

0.89 5-Year SI

SJR 

Q1Oncology

SNIP 

3.17
Recommended pre-submission checks
Powered by 

Topics Covered on Neuro-Oncology
Neuro-Oncology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | OXFORD UNIV PRESS INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Neuro-Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Neuro-Oncology
Phase 2 test of QBS72S for breast cancer leptomeningeal disease.
- 7 Aug 2026
- Neuro-oncology
Focused ultrasound to track circulating extracellular vesicles in glioblastoma.
- 6 Aug 2026
- Neuro-oncology
Beyond the contrast-enhancing margin: AI-guided targeting of glioblastoma infiltration.
- 1 Aug 2026
- Neuro-oncology
A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.
- 1 Aug 2026
- Neuro-oncology
Incidental meningiomas have favorable clinical outcomes across molecular classification systems.
- 1 Aug 2026
- Neuro-oncology
Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
- 1 Aug 2026
- Neuro-oncology
Phase 2 test of QBS72S for breast cancer leptomeningeal disease.
- 7 Aug 2026
- Neuro-oncology
Focused ultrasound to track circulating extracellular vesicles in glioblastoma.
- 6 Aug 2026
- Neuro-oncology
Beyond the contrast-enhancing margin: AI-guided targeting of glioblastoma infiltration.
- 1 Aug 2026
- Neuro-oncology
A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.
- 1 Aug 2026
- Neuro-oncology
Incidental meningiomas have favorable clinical outcomes across molecular classification systems.
- 1 Aug 2026
- Neuro-oncology
Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
- 1 Aug 2026
- Neuro-oncology